- Report
- August 2023
- 295 Pages
Global
From €9169EUR$9,500USD£7,866GBP
- Report
- March 2024
- 200 Pages
Global
From €4006EUR$4,150USD£3,436GBP
- Report
- October 2020
- 209 Pages
Global
From €3074EUR$3,185USD£2,637GBP
€4392EUR$4,550USD£3,767GBP
- Report
- August 2022
- 115 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Drug Pipelines
- January 2023
- 30 Pages
Global
From €2654EUR$2,750USD£2,277GBP
- Report
- August 2022
- 30 Pages
Global
From €2654EUR$2,750USD£2,277GBP
- Report
- January 2022
- 130 Pages
Global
From €6708EUR$6,950USD£5,754GBP
- Report
- August 2018
- 37 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Clinical Trials
- December 2019
- 901 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Clinical Trials
- December 2019
- 876 Pages
Global
From €2413EUR$2,500USD£2,070GBP
- Report
- April 2022
- 188 Pages
Global
From €3475EUR$3,600USD£2,981GBP
- Report
- April 2022
- 85 Pages
Europe
From €1448EUR$1,500USD£1,242GBP
- Report
- February 2024
- 85 Pages
Global
From €3500EUR$3,884USD£3,107GBP
Vedolizumab is a biologic drug used to treat gastrointestinal diseases such as ulcerative colitis and Crohn's disease. It is a monoclonal antibody that binds to the α4β7 integrin, a protein found on the surface of certain white blood cells. This binding prevents the white blood cells from entering the gastrointestinal tract, reducing inflammation and symptoms of the disease. Vedolizumab is administered intravenously and is typically used in combination with other medications.
Vedolizumab is a relatively new drug, having been approved by the US Food and Drug Administration in 2014. It is one of several biologic drugs used to treat gastrointestinal diseases, and is often used when other treatments have failed.
Companies in the Vedolizumab market include Takeda Pharmaceuticals, AbbVie, and UCB. Show Less Read more
